The present invention relates to a specific conjugate of cytotoxic drugs and prodrug forms of said conjugate, for use in treating cancer and inflammatory diseases. The conjugate is represented by formula (I) wherein A represents a radical deriving from a cytotoxic drug, G is a self-immolative moiety, and m is 0 or 1, and pharmaceutically acceptable salts thereof.